Skip to main content

Advertisement

SpringerLink
Log in

Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth

  • Original Article
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. Oncolytic viruses represent a promising therapeutic agent or vehicle to human cancers due to their ability of selectively lysing cancer cells but not in normal cells. TSLC1, a novel tumor suppressor gene, was loss in many human cancers including HCC, not in normal cells. The current study is focused on the antitumor effect of TSLC1-armed survivin-regulated oncolytic adenovirus for HCC and to explore their molecular mechanism.

Methods

The expression of tumor suppressor TSLC1 and survivin was detected by quantitative PCR. The recombinant virus Ad.SP-E1A-E1B(Δ55)-TSLC1 (brief name as SD55-TSLC1) was constructed by inserting TSLC1 gene into the dual-regulated oncolytic adenovirus vector Ad.SP-E1A-E1B(Δ55). Then, we performed the antitumor experiments of SD55-TSLC1 in vitro and in nude mice xenografted with Huh7 liver cancer.

Results

The expression of TSLC1 was lower in HCC cells than in normal cells, which implied TSLC1 is a tumor suppressor of liver cancer. Survivin expression is higher in detected HCC cells than in normal cells. The SD55-TSLC1 exhibited an excellent antitumor effect on HCC cell growth in vitro but does no or little damage to normal liver cells. Animal experiment further confirmed that SD55-TSLC1 achieved significant inhibition of Huh7 liver cancer xenografted growth. Furthermore, the mechanism of antitumor efficacy by SD55-TSLC1 was elucidated to be due to the activation of caspase apoptotic pathway including the inducement of caspase-3, caspase-8, and poly (ADP-ribose) polymerase cleavage. This is the first report of TSLC1 by oncolytic adenovirus with an excellent antitumor effect to liver cancer growth.

Conclusion

These data suggest that an oncolytic adenovirus expressing TSLC1 is effective and support that SD55-TSLC1 may be a potent antitumoral agent for future clinical trials of liver cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  • Borinstein SC, Conerly M, Dzieciatkowski S, Biswas S, Washington MK, Trobridge P, Henikoff S, Grady WM (2011) Aberrant DNA methylation occurs in colon neoplasms arising in the azoxymethane colon cancer model. Mol Carcinog 49:94–103

    Google Scholar 

  • Duffy MJ, O’Donovan N, Brennan DJ, Gallagher WM, Ryan BM (2007) Survivin: a promising tumor biomarker. Cancer Lett 249:49–60

    Article  PubMed  CAS  Google Scholar 

  • Evans J (2011) Recent deal highlights hopes for cancer-killing viruses. Nat Med 17:268–269

    Article  PubMed  CAS  Google Scholar 

  • Fukuhara H, Kuramochi M, Fukami T, Kasahara K, Furuhata M, Nobukuni T, Maruyama T, Isogai K, Sekiya T, Shuin T, Kitamura T, Reeves RH, Murakami Y (2002) Promoter methylation of TSLC1 and tumor suppression by its gene product in human prostate cancer. Jpn J Cancer Res 93:605–609

    Article  PubMed  CAS  Google Scholar 

  • Fukuhara H, Masuda M, Yageta M, Fukami T, Kuramochi M, Maruyama T, Kitamura T, Murakami Y (2003) Association of a lung tumor suppressor TSLC1 with MPP3, a human homologue of Drosophila tumor suppressor Dlg. Oncogene 22:6160–6165

    Article  PubMed  CAS  Google Scholar 

  • Heller G, Geradts J, Ziegler B, Newsham I, Filipits M, Markis-Ritzinger EM, Kandioler D, Berger W, Stiglbauer W, Depisch D, Pirker R, Zielinski CC, Zochbauer-Muller S (2007) Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast Cancer Res Treat 103:283–291

    Article  PubMed  CAS  Google Scholar 

  • Honda T, Tamura G, Waki T, Jin Z, Sato K, Motoyama T, Kawata S, Kimura W, Nishizuka S, Murakami Y (2002) Hypermethylation of the TSLC1 gene promoter in primary gastric cancers and gastric cancer cell lines. Jpn J Cancer Res 93:857–860

    Article  PubMed  CAS  Google Scholar 

  • Hui AB, Lo KW, Kwong J, Lam EC, Chan SY, Chow LS, Chan AS, Teo PM, Huang DP (2003) Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma. Mol Carcinog 38:170–178

    Article  PubMed  CAS  Google Scholar 

  • Igarashi T, Miyake K, Masuda I, Takahashi H, Shimada T (2010) Adeno-associated vector (Type 8)-mediated expression of sflt-1 efficiently inhibits neovascularization in a murine choroidal neovascularization model. Hum Gene Ther 21:631–637

    Google Scholar 

  • Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, Takase K, Moriyama M, Kawano H, Hayashida M, Nakano T, Suzuki A (2000) Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 31:1080–1085

    Article  PubMed  CAS  Google Scholar 

  • Kainuma M, Sakai S, Sekiya N, Mantani N, Ogata N, Shimada Y, Terasawa K (2004) The effects of a herbal medicine (Mao-to) in patients with chronic hepatitis C after injection of IFN-beta. Phytomedicine 11:5–10

    Article  PubMed  CAS  Google Scholar 

  • Kuramochi M, Fukuhara H, Nobukuni T, Kanbe T, Maruyama T, Ghosh HP, Pletcher M, Isomura M, Onizuka M, Kitamura T, Sekiya T, Reeves RH, Murakami Y (2001) TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet 27:427–430

    Article  PubMed  CAS  Google Scholar 

  • Li B, Liu X, Fan J, Qi R, Bo L, Gu J, Qian Q, Qian C (2006) A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo. J Gene Med 8:1232–1242

    Article  PubMed  CAS  Google Scholar 

  • Lin H, van den Esschert J, Liu C, van Gulik TM (2011) Systematic review of hepatocellular adenoma in China and other regions. J Gastroenterol Hepatol 26:28–35

    Article  PubMed  Google Scholar 

  • Liu XY, Gu JF (2006) Targeting gene-virotherapy of cancer. Cell Res 16:25–30

    Article  PubMed  Google Scholar 

  • Lung HL, Cheung AK, Xie D, Cheng Y, Kwong FM, Murakami Y, Guan XY, Sham JS, Chua D, Protopopov AI, Zabarovsky ER, Tsao SW, Stanbridge EJ, Lung ML (2006) TSLC1 is a tumor suppressor gene associated with metastasis in nasopharyngeal carcinoma. Cancer Res 66:9385–9392

    Article  PubMed  CAS  Google Scholar 

  • Mao X, Seidlitz E, Truant R, Hitt M, Ghosh HP (2004) Re-expression of TSLC1 in a non-small-cell lung cancer cell line induces apoptosis and inhibits tumor growth. Oncogene 23:5632–5642

    Article  PubMed  CAS  Google Scholar 

  • Masuda M, Yageta M, Fukuhara H, Kuramochi M, Maruyama T, Nomoto A, Murakami Y (2002) The tumor suppressor protein TSLC1 is involved in cell–cell adhesion. J Biol Chem 277:31014–31019

    Article  PubMed  CAS  Google Scholar 

  • Murakami Y (2005) Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis. Cancer Sci 96:543–552

    Article  PubMed  CAS  Google Scholar 

  • Ohno N, Terada N, Komada M, Saitoh S, Costantini F, Pace V, Germann PG, Weber K, Yamakawa H, Ohara O, Ohno S (2009) Dispensable role of protein 4.1B/DAL-1 in rodent adrenal medulla regarding generation of pheochromocytoma and plasmalemmal localization of TSLC1. Biochim Biophys Acta 1793:506–515

    Article  PubMed  CAS  Google Scholar 

  • Sakurai-Yageta M, Masuda M, Tsuboi Y, Ito A, Murakami Y (2009) Tumor suppressor CADM1 is involved in epithelial cell structure. Biochem Biophys Res Commun 390:977–982

    Article  PubMed  CAS  Google Scholar 

  • Shimizu K, Onishi M, Sugata E, Fujii H, Honoki K, Tsujiuchi T (2007) Aberrant DNA methylation of the 5’ upstream region of Tslc1 gene in hamster pancreatic tumors. Biochem Biophys Res Commun 353:522–526

    Article  PubMed  CAS  Google Scholar 

  • Su C, Na M, Chen J, Wang X, Liu Y, Wang W, Zhang Q, Li L, Long J, Liu X, Wu M, Fan X, Qian Q (2008) Gene-viral cancer therapy using dual-regulated oncolytic adenovirus with antiangiogenesis gene for increased efficacy. Mol Cancer Res 6:568–575

    Article  PubMed  CAS  Google Scholar 

  • Sussan TE, Pletcher MT, Murakami Y, Reeves RH (2005) Tumor suppressor in lung cancer 1 (TSLC1) alters tumorigenic growth properties and gene expression. Mol Cancer 4:28

    Article  PubMed  Google Scholar 

  • Takahashi Y, Iwai M, Kawai T, Arakawa A, Ito T, Sakurai-Yageta M, Ito A, Goto A, Saito M, Kasumi F, Murakami Y (2011) Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer. Breast Cancer [Epub ahead of print]

  • Tamura G (2004) Promoter methylation status of tumor suppressor and tumor-related genes in neoplastic and non-neoplastic gastric epithelia. Histol Histopathol 19:221–228

    PubMed  CAS  Google Scholar 

  • Tamura G (2006) Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World J Gastroenterol 12:192–198

    PubMed  CAS  Google Scholar 

  • Tsanou E, Peschos D, Batistatou A, Charalabopoulos A, Charalabopoulos K (2008) The E-cadherin adhesion molecule and colorectal cancer. A global literature approach. Anticancer Res 28:3815–3826

    PubMed  Google Scholar 

  • Tsujiuchi T, Sugata E, Masaoka T, Onishi M, Fujii H, Shimizu K, Honoki K (2007) Expression and DNA methylation patterns of Tslc1 and Dal-1 genes in hepatocellular carcinomas induced by N-nitrosodiethylamine in rats. Cancer Sci 98:943–948

    Article  PubMed  CAS  Google Scholar 

  • Uchida H, Tanaka T, Sasaki K, Kato K, Dehari H, Ito Y, Kobune M, Miyagishi M, Taira K, Tahara H, Hamada H (2004) Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther 10:162–171

    Article  PubMed  CAS  Google Scholar 

  • Ulasov IV, Zhu ZB, Tyler MA, Han Y, Rivera AA, Khramtsov A, Curiel DT, Lesniak MS (2007) Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther 18:589–602

    Article  PubMed  CAS  Google Scholar 

  • van der Laan LJ, Wang Y, Tilanus HW, Janssen HL, Pan Q (2011) AAV-mediated gene therapy for liver diseases: the prime candidate for clinical application? Expert Opin Biol Ther 11:315–327

    Article  PubMed  Google Scholar 

  • Zhang ZL, Zou WG, Luo CX, Li BH, Wang JH, Sun LY, Qian QJ, Liu XY (2003) An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res 13:481–489

    Article  PubMed  CAS  Google Scholar 

  • Zhang Y, Ma H, Liu SL, Liu YX, Zheng DX (2008) Effects of human telomerase reverse transcriptase promoter and survivin promoter in targeted tumor gene therapy. Zhonghua Yi Xue Za Zhi 88:475–479

    PubMed  CAS  Google Scholar 

  • Zhang KJ, Wang YG, Cao X, Zhong SY, Wei RC, Wu YM, Yue XT, Li GC, Liu XY (2009) Potent antitumor effect of interleukin-24 gene in the survivin promoter and retinoblastoma double-regulated oncolytic adenovirus. Hum Gene Ther 20:818–830

    Article  PubMed  CAS  Google Scholar 

  • Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He L, Wang Y, Zhang J, Zhang Z, Huiwang J, Qian Q, Qian C, Liu X (2005) Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene Ther 16:845–858

    Article  PubMed  CAS  Google Scholar 

  • Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA, Barker S, Yamaoto M, Li F, Alvarez RD, Curiel DT (2004) Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther 11:256–262

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank Dr. R. Steenbergen of Vrije Universiteit Medical Center for providing TSLC1 cDNA clone. This work was supported by Zhejiang Sci-Tech University Study Start-up grants (1016834-Y and 1016845-Y), Zhejiang Natural Science Foundation (No. Y2090935) and the National Nature Science Foundation of China (No. 30800093).

Conflict of interest

We have no potential conflict of interest to disclose.

Author information

Authors and Affiliations

  1. Xinyuan Institute of Medicine and Biotechnology, School of Life Sciences, Zhejiang Sci-Tech University, No. 2 Road Xiasha District, Hangzhou, 310018, China

    Guoqing He, Wen Lei, Shibin Wang, Ruijuan Xiao, Keni Guo, Yulong Xia, Xiumei Zhou, Xinyuan Liu & Yigang Wang

  2. Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, 200031, China

    Kangjian Zhang

Authors
  1. Guoqing He
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wen Lei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shibin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ruijuan Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Keni Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yulong Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiumei Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kangjian Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Xinyuan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yigang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xinyuan Liu or Yigang Wang.

Additional information

Guoqing He and Wen Lei have contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

He, G., Lei, W., Wang, S. et al. Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth. J Cancer Res Clin Oncol 138, 657–670 (2012). https://doi.org/10.1007/s00432-011-1138-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-011-1138-2

Keywords

Search

Navigation